Previous 10 | Next 10 |
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a c...
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q3 2021 Earnings Call Nov 04, 2021 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) Q3 2021 Earnings Conference Call November 04, 2021 08:45 AM ET Company Participants Lisa Caperelli - Vice President or Investor Relations Bill Collier - President and Chief Executive Officer Dave Hastings - Chief Financial Officer Gaston Picchio - Chief De...
Arbutus Biopharma (NASDAQ:ABUS): Q3 GAAP EPS of -$0.24 in-line. Revenue of $3.34M (+119.7% Y/Y) beats by $0.93M. Shares +0.78% PM. Cash equivalents and investments in marketable securities totaling $151.9 million as of September 30, 2021 Press Release For further details see: Arbutus Bi...
On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021 First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog (“NA”) therapy On-track to initiate several proof-of-concept Phase 2a clinical t...
Arbutus Biopharma (NASDAQ:ABUS) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $2.41M (+58.6% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 d...
ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provid...
We’re just days away from October, going in the books and heading into mid-Q4. Of course, penny stocks are at the top of mind, and new trends continue emerging. With the rise of meme stocks this year, there’s been a clear focus on a market phenomenon known as a short squeeze, ...
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provid...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...